Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042662 | 1.00 | DRD4 (0.46) | DRD4DRD2BCHEACHEBACE1 | |
| SCHEMBL6652157 | 0.91 | CYP2D6 (0.51) | DRD4DRD2CYP2D6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10431124 | 0.89 | CYP2D6 (0.46) | CYP2D6SIGMAR1 | |
| SCHEMBL6041799 | 0.88 | ACHE (0.41) | DRD4DRD2BCHEACHEBACE1 | |
| SCHEMBL6041801 | 0.88 | ACHE (0.41) | DRD4DRD2BCHEACHEBACE1 | |
| SCHEMBL7466037 | 0.87 | DRD2 (0.44) | DRD4DRD2ACHESLC6A12TMEM97 | |
| SCHEMBL6041243 | 0.87 | ALDH1A1 (0.45) | BCHEACHEBACE1CYP2D6HTT | |
| SCHEMBL6041242 | 0.87 | ALDH1A1 (0.45) | BCHEACHEBACE1CYP2D6HTT | |
| SCHEMBL7238857 | 0.87 | LMNA (0.42) | DRD4DRD2KDM4EMCHR1 | |
| SCHEMBL7466045 | 0.85 | DRD2 (0.42) | DRD4DRD2CYP2D6SLC6A12TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838700-B2 | Recovery and recycling of chiral tartaric acid resolving agents | AESICA PHARMACEUTICALS (GB) | 2010-11-23 | — | — | US | disclosed |
| EP-1446372-B1 | RECOVERY AND RECYCLING OF CHIRAL TARTARIC ACID RESOLVING AGENTS | AESICA PHARMACEUTICALS LTD (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-1315701-B1 | PROCESS FOR THE RACEMISATION OF 1-BENZYL-4-(4-FLUOROPHENYL)-3-HYDROXYMETHYL-1,2,3,6-TETRAHYDROPYRIDINE TO BE USED AS INTERMEDIATE IN THE SYNTHESIS OF PAROXETINE | AESICA PHARMACEUTICALS LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| EP-1315701-B1 | PROCESS FOR THE RACEMISATION OF 1-BENZYL-4-(4-FLUOROPHENYL)-3-HYDROXYMETHYL-1,2,3,6-TETRAHYDROPYRIDINE TO BE USED AS INTERMEDIATE IN THE SYNTHESIS OF PAROXETINE | AESICA PHARMACEUTICALS LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| EP-1315701-B1 | PROCESS FOR THE RACEMISATION OF 1-BENZYL-4-(4-FLUOROPHENYL)-3-HYDROXYMETHYL-1,2,3,6-TETRAHYDROPYRIDINE TO BE USED AS INTERMEDIATE IN THE SYNTHESIS OF PAROXETINE | AESICA PHARMACEUTICALS LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| CN-1256326-C | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-6949650-B2 | Process for the racemization of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2-3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine | AESICA PHARMACEUTICALS LTD. (GB) | 2005-09-27 | — | — | US | disclosed |
| US-6949650-B2 | Process for the racemization of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2-3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine | AESICA PHARMACEUTICALS LTD. (GB) | 2005-09-27 | — | — | US | disclosed |
| US-6949650-B2 | Process for the racemization of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2-3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine | AESICA PHARMACEUTICALS LTD. (GB) | 2005-09-27 | — | — | US | disclosed |
| WO-2001025201-A1 | PROCESS FOR THE PREPARATION OF PAROXETIN INTERMEDIATE | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-12 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0983237-A1 | CHEMICAL PROCESS FOR THE REDUCTION OF 1-SUBSTITUTED -3-HYDROXYMETHYL-4- (4-FLUOROPHENYL)TETRAHYDROPYRIDINES | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-03-08 | — | — | EP | disclosed |
| EP-0923554-A1 | N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1999-06-23 | — | — | EP | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| WO-1998052920-A1 | CHEMICAL PROCESS FOR THE REDUCTION OF 1-SUBSTITUTED -3-HYDROXYMETHYL-4- (4-FLUOROPHENYL)TETRAHYDROPYRIDINES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-11-26 | — | — | WO | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998001424-A1 | N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | DRD4 2414/4885DRD2 2550/4885BCHE 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.